Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity

Table 1 Nevin staging system for gallbladder cancer[18]

Stage	Definitions
1	Tumor invades mucosa only
2	Tumor invades muscularis and mucosa
3	Tumor invades subserosa, muscularis, and mucosa
4	Tumor invades all layers of gallbladder wall plus cystic lymph node
5	Tumor extension into liver bed or distant spread

Table 2 Clinicopathologic characteristics of MVC in gallbladder carcinoma (mean ± SD)

Characteristics	n	MVC
Tumor differentiation
Good	22	30 ± 11
Moderate-poor	27	38 ± 11a
Nevin staging
S1, S2, S3	19	26 ± 11
S4, S5	30	40 ± 8b
Lymph node metastasis
Yes	27	40 ± 10
No	22	28 ± 11d

^aP<0.05 vs good group;

^bP<0.01 vs“S1, S2, S3” group;

^dP<0.01 vs yes group.

Table 3 Clinicopathologic characteristics of VEGF expression in gallbladder carcinoma

Characteristics	n	+	%
Tumor differentiation
Good	22	15	68.2
Moderate-poor	27	16	59.3
Nevin staging
S1, S2, S3	19	8	42.1
S4, S5	30	23	76.7a
Lymph node metastasis
Yes	27	21	77.8
No	22	12	54.5c

^aP<0.05 vs“S1, S2, S3” group;

^cP<0.05 vs yes group.

Table 4 Clinicopathologic characteristics of mutant p53 expression in gallbladder carcinoma

Characteristics	n	+	%
Tumor differentiation
Good	22	13	59.1
Moderate-poor	27	17	63
Nevin staging
S1, S2, S3	19	9	47.4
S4, S5	30	21	70.0a
Lymph node metastasis
Yes	27	20	74.1
No	22	10	45.5c

^aP<0.05 vs“S1, S2, S3” group;

^cP<0.05 vs yes group.

Table 5 Relationship between MVC and presence of p53 and VEGF (mean ± SD, n (%))

	Patients,	MVC	Total
	VEGF(+)	VEGF(-)
p53(+)	27 (55.1%)	3 (6.1%)	30 (61.2%)
	41 ±  9	35 ± 10	36 ± 10
p53(-)	4 (8.2%)	15 (30.6%)	19 (38.8%)
	36 ± 12	28 ± 13a	30 ± 12e
Total	31 (63.3%)	18 (36.7%)	49 (100%)
	37 ± 11	30 ± 12c

^aP<0.05 vs others,

^cP<0.05 vs “VEGF(+)” group,

^eP<0.05 vs“p53(+)” group.